We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.76B
AUM Growth
+$192M
Cap. Flow
+$562M
Cap. Flow %
20.4%
Top 10 Hldgs %
46.52%
Holding
86
New
11
Increased
24
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$117M
2
CGEM icon
Cullinan Oncology
CGEM
+$92.4M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$74.2M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$51.3M
5
CRNX
Crinetics Pharmaceuticals
CRNX
+$50.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$45.6M
2
RVMD icon
Revolution Medicines
RVMD
+$19M
3
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$16.5M
4
ANAB icon
AnaptysBio
ANAB
+$9.07M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$7.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.18%
2 Financials 0.46%
3 Miscellaneous 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JYAC
76
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.93M 0.11%
300,000
– –
FWP
77
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.58M 0.09%
432,892
– –
ABOS icon
78
Acumen Pharmaceuticals
ABOS
$205M
$1.96M 0.07%
289,663
– –
XFOR icon
79
X4 Pharmaceuticals
XFOR
$341M
$1.94M 0.07%
28,263
– –
GBIO
80
DELISTED
Generation Bio
GBIO
$1.34M 0.05%
+18,905
New +$3.3M
NEUP
81
Neuphoria Therapeutics
NEUP
$20.5M
$1.02M 0.04%
+6,748
New +$1.04M
RZLT icon
82
Rezolute
RZLT
$389M
$912K 0.03%
190,815
– –
VYGR icon
83
Voyager Therapeutics
VYGR
$186M
$60K ﹤0.01%
+22,200
New +$75.7K
ANAB icon
84
AnaptysBio
ANAB
$1.6B
– –
-334,398
Closed -$9.07M
MRUS
85
CALL
DELISTED
Merus
MRUS
– –
-5,060,071
Closed -$111M
GRTS
86
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-1,528,072
Closed -$16.5M
1 2 3
4

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q4 2021 Portfolio in Review

As of Q4 2021, BVF Inc held 86 positions worth $2.76B, up 7.5% from $2.56B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

BVF Inc deployed $562M of net new capital in Q4 2021, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Merus: 4,135,071 shares worth $131M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was argenx, an estimated $45.6M trimmed.

  • BVF Inc's largest Q4 2021 buy was Merus: 4,135,071 shares worth $131M.
  • BVF Inc added most to Cullinan Oncology in Q4 2021, an estimated $92.4M increase.
  • BVF Inc's biggest Q4 2021 reduction was argenx, cutting an estimated $45.6M.
  • BVF Inc fully exited Gritstone bio, Inc. Common Stock in Q4 2021, selling an estimated $16.5M.
  • BVF Inc's ten largest holdings make up 47% of its $2.76B portfolio in Q4 2021.
  • BVF Inc opened 11 new positions and closed 3 in Q4 2021.
  • BVF Inc's portfolio value rose 7.5% quarter-over-quarter to $2.76B.

Based on BVF Inc's 13F filing for Q4 2021, filed 14 Feb 2022.